Women with endometriosis frequently experience psychological and sexual concerns. Combined oral contraceptives (COCs) and progestin-only pills (POPs) represent first-line treatments for the disease, yet their potential negative impact on mood …
To evaluate the efficacy and tolerability of the gonadotropin-releasing hormone antagonist elagolix for endometriosis-associated pain symptoms in adolescents and young adults (AYA).
LY01021 is a novel oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of various sex hormone-dependent disorders. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), …
Endometriosis is a common, chronic disease with a high burden for women, characterised by the implantation of endometrial cells outside the uterus. Many different treatments have been proposed for this …
Background: The management of endometriosis-associated pain has traditionally focused on analgesic efficacy. However, with high-level evidence demonstrating therapeutic equivalence among principal hormonal classes, the paradigm has shifted towards a patient-centred …
Endometriosis contributes to 5-21% of hospital admissions for pelvic pain. While hormonal therapies are pivotal in managing endometriosis-related pain, no single hormonal treatment suits all patients. We aimed to assess …
Uterine fibroids and endometriosis are among the most common conditions encountered in gynaecological practice. Fibroids affect 30-70% of women, with up to half experiencing symptoms that significantly impair quality of …
Infigratinib shows promising efficacy and tolerability in pediatric achondroplasia 2 Minute Medicine
Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …
Although topical corticosteroids (TCS) represent first-line treatment for vulvar lichen sclerosus (VLS) and as such should be prescribed to all women at time of diagnosis, approximately 30% of patients do …